Fennec Pharmaceuticals (NASDAQ:FENC) executives outlined the company’s commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference.
Ram Selvaraju, managing director and senior healthcare equity research analyst at H.C. Wainwright, introduced the company and said H.C. Wainwright covers Fennec with a buy rating and a 12-month price target of $13 per share. Fennec Chief Executive Officer Jeff Hackman and Chief Financial Officer Robert Andrade discussed PEDMARK’s market opportunity, recent revenue performance, international plans and patent position.
